<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Risk stratification after non-ST elevation acute coronary syndrome</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Risk stratification after non-ST elevation acute coronary syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Risk stratification after non-ST elevation acute coronary syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Simons, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph S Alpert, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter WF Wilson, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey A Breall, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Pamela S Douglas, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher P Cannon, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Juan Carlos Kaski, DSc, MD, DM (Hons), FRCP, FESC, FACC, FAHA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allan S Jaffe, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patricia A Pellikka, MD, FACC, FAHA, FASE</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 23, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>All patients with non-ST elevation acute coronary syndromes (NSTEACS), which includes unstable angina and non-ST elevation myocardial infarction (NSTEMI), should undergo early and late risk stratification. This process impacts decision making regarding treatment and provides the patient with some sense of what the future holds.</p><p>The general approach to risk stratification for patients with NSTEACS will be reviewed here. Risk stratification is accomplished with the use of validated risk prediction models that include the most important predictors of outcome. These individual predictors are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/77.html" rel="external">"Risk factors for adverse outcomes after non-ST elevation acute coronary syndromes"</a>.)</p><p>It should be noted that this topic addresses risk stratification after a common atherosclerotic plaque rupture MI. However, there are many different pathogenetic mechanisms for NSTEACS, and prognosis will vary based on the mechanism. Examples of other mechanisms of NSTEACS include spontaneous coronary artery dissection and oxygen supply-demand mismatch. (See  <a class="medical medical_review" href="/z/d/html/97665.html" rel="external">"Spontaneous coronary artery dissection"</a> and  <a class="medical medical_review" href="/z/d/html/52.html" rel="external">"Diagnosis of acute myocardial infarction", section on 'Joint Task Force definitions'</a>.)</p><p>Risk stratification for patients with an acute ST elevation MI (STEMI) and for those at risk for life-threatening arrhythmias is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/78.html" rel="external">"Risk stratification after acute ST-elevation myocardial infarction"</a> and  <a class="medical medical_review" href="/z/d/html/1052.html" rel="external">"Incidence of and risk stratification for sudden cardiac death after myocardial infarction"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">VERY HIGH-RISK PATIENTS</span><span class="headingEndMark"> — </span><strong>Individuals with any one of the following clinical characteristics are deemed to be at such high risk that formal early risk stratification is not necessary.</strong> These patients typically need to proceed to urgent coronary angiography:</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiogenic shock</p><p class="bulletIndent1"><span class="glyph">●</span>Overt heart failure (HF) or severe left ventricular dysfunction</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent or persistent rest angina despite intensive medical therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Hemodynamic instability due to mechanical complications (eg, acute mitral regurgitation, ventricular septal defect)</p><p class="bulletIndent1"><span class="glyph">●</span>Unstable ventricular arrhythmias</p><p></p><p>This issue is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/46.html" rel="external">"Non-ST-elevation acute coronary syndromes: Selecting an approach to revascularization"</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">EARLY RISK STRATIFICATION TOOLS</span><span class="headingEndMark"> — </span>Patients with NSTEACS who lack features indicating the need for immediate intervention (see <a class="local">'Very high-risk patients'</a> above) should undergo early risk stratification as soon as possible after the diagnosis is secured to identify individuals who should be treated with an early invasive strategy. We recommend risk stratification, using validated risk prediction tools, of all such patients, particularly those with ST-depression on the electrocardiogram or elevated cardiac biomarkers. We use the Global Registry of Acute Coronary Events (GRACE) or Thrombolysis in Myocardial Infarction (TIMI) tools, as they are derived from large populations and have been well validated in this setting [<a href="#rid1">1</a>]. </p><p>However, most of these individuals undergo early angiography in the absence of a contraindication in our hospitals. (See  <a class="medical medical_review" href="/z/d/html/46.html" rel="external">"Non-ST-elevation acute coronary syndromes: Selecting an approach to revascularization"</a>.)</p><p>The results of early risk stratification are also used to predict 30-day and long-term outcomes. For example, for lower-risk patients with chest pain, but no ST-segment deviation on the first electrocardiogram, and normal troponin levels, the risk of death or myocardial infarction may be as low as 6.7 percent at one year [<a href="#rid2">2</a>]. </p><p>The following are validated risk prediction models or tools that can be used early into the care of patients hospitalized with NSTEACS. These tools differ somewhat in their populations, outcomes, and time frames. </p><p class="headingAnchor" id="H7"><span class="h2">TIMI risk score</span><span class="headingEndMark"> — </span>Analysis of data from the TIMI 11B and ESSENCE trials found seven variables to be independently predictive of outcome in patients with unstable angina or an NSTEMI. These criteria were defined as the TIMI risk score  (<a class="graphic graphic_figure graphicRef67473" href="/z/d/graphic/67473.html" rel="external">figure 1</a>). To calculate the score, a value of 1 is assigned when each variable was present and 0 when it was absent [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Age ≥65 years</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of at least three risk factors for coronary heart disease (CHD)</p><p class="bulletIndent1"><span class="glyph">●</span>Prior coronary stenosis of ≥50 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of ST segment deviation on admission ECG</p><p class="bulletIndent1"><span class="glyph">●</span>At least two anginal episodes in prior 24 hours</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated serum cardiac biomarkers</p><p class="bulletIndent1"><span class="glyph">●</span>Use of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> in prior seven days</p><p></p><p>A higher TIMI risk score correlated significantly with increased numbers of events (all-cause mortality, new or recurrent MI, or severe recurrent ischemia requiring revascularization) at <strong>14 days</strong> (<a class="calc calc_professional" href="/z/d/html/13466.html" rel="external">calculator 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Score of 0/1 – 4.7 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Score of 2 – 8.3 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Score of 3 – 13.2 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Score of 4 – 19.9 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Score of 5 – 26.2 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Score of 6/7 – 40.9 percent</p><p></p><p>The TIMI risk score has been validated in multiple cohorts [<a href="#rid4">4,5</a>].</p><p>A similar predictive value has been noted for post-discharge events at six weeks [<a href="#rid6">6</a>] and for major cardiac events at 30 days in patients who have undergone percutaneous coronary intervention (PCI). (See  <a class="medical medical_review" href="/z/d/html/46.html" rel="external">"Non-ST-elevation acute coronary syndromes: Selecting an approach to revascularization"</a>.)</p><p>Not surprisingly, higher TIMI risk scores have been correlated with more severe angiographic disease. In an analysis from PRISM-PLUS, increasing TIMI risk scores from 0 to 2 (low risk) to 5 to 7 (high risk) were associated with progressive increases in the frequency of high-risk angiographic findings such as severe (&gt;70 percent) culprit stenosis (from 58 to 81 percent), multivessel disease (43 to 80 percent), visible thrombus (30 to 41 percent), and left main disease [<a href="#rid7">7</a>].</p><p>The TIMI risk score can also identify patients most likely to benefit from particular therapies:</p><p class="bulletIndent1"><span class="glyph">●</span>In TACTICS-TIMI 18, only patients at moderate to high risk (score ≥3) benefited from an early invasive strategy [<a href="#rid8">8</a>]. The presence of biomarker elevation and ST segment deviation are two of the TIMI risk score variables. However, a later analysis from TACTICS-TIMI 18 showed that the degree of troponin elevation and magnitude of ST segment deviation were independent predictors of an adverse outcome and of benefit from an early invasive strategy [<a href="#rid9">9</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In PRISM-PLUS, only patients with a score ≥4 benefited from the addition of <a class="drug drug_general" data-topicid="10288" href="/z/d/drug information/10288.html" rel="external">tirofiban</a> to heparin [<a href="#rid4">4</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In TIMI 11B and ESSENCE, <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> was associated with better 14-day and six-week post-discharge outcomes compared to <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a>; these benefits were primarily seen in high-risk patients with risk scores ≥4 and ≥5, respectively [<a href="#rid3">3,6</a>]. </p><p></p><p class="headingAnchor" id="H8"><span class="h3">TIMI risk index</span><span class="headingEndMark"> — </span>The TIMI risk index (TRI) is a simpler model derived from the InTIME-II trial of fibrinolytic therapy for ST elevation MI. It can be used simultaneously with the TIMI risk score. (See  <a class="medical medical_review" href="/z/d/html/78.html" rel="external">"Risk stratification after acute ST-elevation myocardial infarction", section on 'TIMI risk index'</a>.)</p><p>The TRI is calculated from the following equation, using data obtained at presentation  (<a class="graphic graphic_table graphicRef52542" href="/z/d/graphic/52542.html" rel="external">table 1</a>) [<a href="#rid10">10</a>]:</p><p>  TRI  =  (Heart rate  x  [age/10] squared)  ÷  systolic pressure</p><p>When applied to over 337,000 patients with non-ST elevation MI in the National Registry of Myocardial Infarction (NRMI) in the United States, there was a graded relationship to in-hospital mortality, ranging from 1.0 to 34.4 percent from the lowest (0 to &lt;10) to the highest scores (≥80) [<a href="#rid11">11</a>]. Patients with a TRI &lt;30 were at low risk. Patients with higher risk indices were more often Killip class &gt;1 and had more frequent comorbidities such as heart failure, renal failure, and chronic obstructive pulmonary disease.</p><p class="headingAnchor" id="H10"><span class="h2">GRACE risk model</span><span class="headingEndMark"> — </span>The GRACE risk model (and score) discussed below is uncommonly used by our contributors. The model was developed prior to the validation of high-sensitivity (hs) troponin as a reliable single prognostic variable, and it does not appear to add any significant prognostic information to hs troponin. </p><p>The TIMI risk score, while extensively validated as described above, is derived from two clinical trial databases. The GRACE registry, a global registry of ACS patients from 94 hospitals in 14 countries, developed two models to estimate the risk of <strong>in-hospital</strong> and <strong>six-month</strong> mortality among all patients with an ACS, an end point different from the composite end point in the TIMI risk score. </p><p>The <strong>in-hospital GRACE</strong> model  (<a class="graphic graphic_table graphicRef88782" href="/z/d/graphic/88782.html" rel="external">table 2</a>) was based upon data from 11,389 patients with either an STEMI or an NSTEACS [<a href="#rid12">12</a>]. This model was then validated based upon data from an additional 3972 patients from GRACE and 12,142 patients from the GUSTO IIb trial. Eight independent risk factors were found to account for almost 90 percent of the prognostic information:</p><p class="bulletIndent1"><span class="glyph">●</span>Age</p><p class="bulletIndent1"><span class="glyph">●</span>Killip class (see  <a class="medical medical_review" href="/z/d/html/77.html" rel="external">"Risk factors for adverse outcomes after non-ST elevation acute coronary syndromes", section on 'Killip class'</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Systolic blood pressure</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of ST segment deviation</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac arrest during presentation</p><p class="bulletIndent1"><span class="glyph">●</span>Serum creatinine concentration</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of elevated serum cardiac biomarkers</p><p class="bulletIndent1"><span class="glyph">●</span>Heart rate</p><p></p><p>Point scores were assigned for each predictive factor and are added together to arrive at an estimate of the risk of in-hospital mortality. A nomogram was published with the GRACE risk model to allow calculation of the risk score. Software is available at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.outcomes-umassmed.org%2Fgrace%2F&amp;token=mJ2XuLqdLLe0%2BA8rZisyxtXv6ac9FeirbC%2BJJlZ%2Fx9DbzFIr8cPd5GvH9Zgip9aUrwC1JCwUsNIWoeWxLU0oqw%3D%3D&amp;TOPIC_ID=76" target="_blank">https://www.outcomes-umassmed.org/grace/</a> to enable calculation of the GRACE risk score (<a class="calc calc_professional" href="/z/d/html/118467.html" rel="external">calculator 2</a>).</p><p>Although designed to assess the risk of in-hospital mortality, this GRACE risk model also predicts mortality or recurrent MI at six months and at one year. Its predictive value at one year is slightly greater than that for the TIMI risk score [<a href="#rid13">13,14</a>].</p><p>The six-month mortality GRACE model was based upon data from 15,007 patients and validated in a cohort of 7638 patients, all in the GRACE registry [<a href="#rid15">15</a>]. The variables incorporated into this model include age, prior history of heart failure, prior history of myocardial infarction, resting heart rate, systolic blood pressure, ST-segment depression, initial serum creatinine concentration, elevated serum cardiac biomarkers, and performance of in-hospital PCI. The six-month mortality risk based upon this model can be calculated using the website <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.outcomes-umassmed.org%2Fgrace%2F&amp;token=erEtv2h4SKbehy52hBNFQ4C8qBxX5%2BoV2yJv4xO%2BcQuKc9kv1XSieCg%2B%2F7gTuIMn&amp;TOPIC_ID=76" target="_blank">www.outcomes-umassmed.org/grace/</a>.</p><p>To improve the usability of the score, the GRACE investigators developed the GRACE risk score 2.0 and electronic tools to assist with the calculation (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.outcomes-umassmed.org%2Fgrace%2Facs_risk2%2Findex.html&amp;token=SpjPJGDOdadG2c%2ButmgCQHohCkZ0c%2FTv2jHdhMiCNqRqzb7ZlmkgmQ8EFxxQP3DA%2FWB5Dy5y2kpy8pxKB0gl9tH9H1VFIfABXEVaJIkxs5w%3D&amp;TOPIC_ID=76" target="_blank">https://www.outcomes-umassmed.org/grace/acs_risk2/index.html</a>) [<a href="#rid16">16</a>]. The score provides prognosis at six months, one year, and three years and was developed in over 30,000 patients with ACS and validated externally in a registry of nearly 3000 patients. Significant nonlinear associations were found for age, systolic blood pressure, pulse, and creatinine. Overall, clinicians should find it easier to use the Grace Score 2.0 and recommend its use compared to prior iterations. </p><p class="headingAnchor" id="H375007354"><span class="h2">CRUSADE long-term mortality risk score</span><span class="headingEndMark"> — </span>Using the CRUSADE registry, over 43,000 patients ≥65 years were used to develop a long-term mortality risk score [<a href="#rid17">17</a>]. The model includes 13 variables and shows good discrimination in the derivation and validation samples. </p><p class="headingAnchor" id="H274988234"><span class="h2">ACTION registry score</span><span class="headingEndMark"> — </span>The Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry was used to develop a risk score to predict in-hospital mortality following STEMI and NSTEMI [<a href="#rid18">18</a>]. Multivariable analyses of data from 243,440 patients showed that greater heart rate, lower systolic blood pressure, life-threatening presentations (cardiac arrest, cardiogenic shock, or heart failure), STEMI at presentation, lower creatinine clearance, and higher troponin values were associated with death during the hospitalization. The C statistic was very good at 0.88.</p><p>The ACTION score is likely to be most helpful for persons with moderate to severe disease and reflects more contemporary experience than TIMI or GRACE. </p><p class="headingAnchor" id="H375004480"><span class="h1">USING THE RESULTS OF EARLY RISK STRATIFICATION</span><span class="headingEndMark"> — </span>Patients at high risk as determined by the use of the risk scores discussed above are usually referred for angiography, if it has not already been performed. For intermediate and low-risk patients who do not undergo early angiography, noninvasive testing prior to discharge may provide information that leads to a decision to perform angiography.</p><p class="headingAnchor" id="H13"><span class="h1">LATE RISK STRATIFICATION</span><span class="headingEndMark"> — </span>Late risk stratification, performed three to seven days after the event, helps in determining long-term management and prognosis. The importance of risk stratification prior to discharge is illustrated by the observation that, among all major cardiac events that occur in the first six weeks, approximately one-fourth occur after discharge [<a href="#rid6">6</a>]. </p><p>The main components are measurement of the left ventricular ejection fraction and, primarily in medically managed patients, stress testing to detect possible residual ischemia. The potential use of continuous ST-segment monitoring is also discussed.</p><p class="headingAnchor" id="H961312073"><span class="h2">Absence of significant coronary disease</span><span class="headingEndMark"> — </span>In different clinical trials, as well as in the CRUSADE registry, 9 to 14 percent of patients with a non-ST elevation acute coronary syndrome (NSTEACS) who undergo early angiography have no significant coronary stenosis [<a href="#rid8">8,19-22</a>]. Approximately one-half of these patients have no coronary stenosis and one-half have a noncritical (less than 50 to 60 percent) coronary stenosis [<a href="#rid19">19-21</a>]. (See  <a class="medical medical_review" href="/z/d/html/43.html" rel="external">"Acute coronary syndrome: Terminology and classification", section on 'Absence of significant coronary disease'</a>.)</p><p>Such patients have a much better short-term prognosis than those with a critical culprit lesion. In a report from the PURSUIT trial, for example, the patients with no or mild coronary disease had a much lower rate of death or nonfatal myocardial infarction (MI) at 30 days than those with significant disease (2 and 6 versus 17 percent) [<a href="#rid20">20</a>]. Similar findings were noted in a report from the CRUSADE registry [<a href="#rid22">22</a>]. Among patients with a non-ST elevation myocardial infarction (NSTEMI), the in-hospital death rate was significantly lower in the patients without significant coronary disease (0.65 versus 2.36 percent for those with coronary disease).</p><p>Outcomes at one year in patients with normal or mild disease were provided in an analysis of 7656 patients pooled from three TIMI trials, which looked at a composite primary end point of death, MI, unstable angina requiring hospitalization, revascularization, or stroke [<a href="#rid19">19</a>]. Among the 710 (9 percent) patients with nonobstructive coronary artery disease, a primary end point occurred in 12 percent, including an event rate of 2 percent for death and MI.</p><p class="headingAnchor" id="H14"><span class="h2">Left ventricular function</span><span class="headingEndMark"> — </span>Assessment of resting left ventricular function is an important part of risk stratification in patients with an NSTEACS and is recommended in all patients [<a href="#rid1">1,23</a>]. Patients with left ventricular systolic dysfunction have increased mortality at long-term follow-up and more than a 50 percent probability of having multivessel coronary disease [<a href="#rid24">24</a>]. </p><p>In the absence of a specific indication (eg, heart failure or suspected mechanical complication), the left ventricular ejection fraction (LVEF) is usually measured before discharge. However, early measurements may be misleading, since improvement in LVEF, beginning within three days and largely complete by 14 days, is common in patients who either reperfuse spontaneously or undergo percutaneous coronary intervention (PCI), a presumed reflection, at least in part, of recovery from myocardial stunning [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/z/d/html/1527.html" rel="external">"Clinical syndromes of stunned or hibernating myocardium", section on 'Acute myocardial infarction'</a>.)</p><p>Multiple imaging techniques for assessing left ventricular function are available and each has equivalent prognostic value in the post-MI patient. In general, echocardiography should be used for routine assessment of LVEF after an NSTEACS. Among patients who have had a non-ST elevation myocardial infarction (NSTEMI), it has the added advantage of detecting other factors that can be associated with a worse prognosis such as diastolic dysfunction, concurrent right ventricular dysfunction, increased left atrial volume, mitral regurgitation, and a high wall motion score index, which reflects a more severe impairment in overall left ventricular systolic function [<a href="#rid26">26-31</a>]. (See  <a class="medical medical_review" href="/z/d/html/79.html" rel="external">"Role of echocardiography in acute myocardial infarction", section on 'Left ventricular systolic function'</a> and  <a class="medical medical_review" href="/z/d/html/79.html" rel="external">"Role of echocardiography in acute myocardial infarction", section on 'Left ventricular diastolic function'</a> and  <a class="medical medical_review" href="/z/d/html/102361.html" rel="external">"Chronic secondary mitral regurgitation: General management and prognosis"</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Stress testing</span><span class="headingEndMark"> — </span>Stress testing, usually with exercise, can be used to detect residual ischemia and to assess the exercise capacity needed for the cardiac rehabilitation exercise prescription. (See  <a class="medical medical_review" href="/z/d/html/1494.html" rel="external">"Exercise ECG testing: Performing the test and interpreting the ECG results"</a>.)</p><p>The primary role of stress testing is to distinguish between higher-risk subjects with severe and/or extensive ischemia who would have improved outcomes with revascularization, and lower-risk subjects with no or limited ischemia who would have comparable outcomes with medical therapy alone. Pre-discharge stress testing is generally not performed in patients who have undergone PCI or coronary artery bypass graft surgery (CABG) and have been fully revascularized (eg, single vessel disease and successful PCI). </p><p>Stress testing for risk stratification in patients with recent NSTEACS is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5318.html" rel="external">"Stress testing in pre-discharge risk stratification of patients with non-ST elevation acute coronary syndrome"</a>.)</p><p class="headingAnchor" id="H21"><span class="h2">Continuous electrocardiography</span><span class="headingEndMark"> — </span>Silent ischemia detected on continuous electrocardiography (continuous ST-segment monitoring) is associated with an increased short-term risk of cardiovascular events. (See  <a class="medical medical_review" href="/z/d/html/77.html" rel="external">"Risk factors for adverse outcomes after non-ST elevation acute coronary syndromes", section on 'Silent ischemia'</a>.)</p><p>Similar findings have been noted at longer-term follow-up [<a href="#rid32">32,33</a>]. In the MERLIN-TIMI 36 trial, which compared <a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">ranolazine</a> to placebo in patients with NSTEMI, 6355 patients underwent an average of six days of uninterrupted 2-lead (Holter) monitoring [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/1524.html" rel="external">"New therapies for angina pectoris", section on 'Acute coronary syndrome'</a>.)</p><p>One or more transient ischemic episodes were noted in 20 percent of patients. After a median follow-up of almost one year, the patients with transient ischemic episodes had significant increases in the risk of cardiovascular death (7.7 versus 2.7 percent), MI (9.4 versus 5.0 percent), and recurrent ischemia (17.5 versus 12.3 percent). The association between transient ischemic episodes and symptomatic ischemia was not assessed.</p><p class="headingAnchor" id="H3826459586"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/114034.html" rel="external">"Society guideline links: Non-ST-elevation acute coronary syndromes (non-ST-elevation myocardial infarction)"</a>.)</p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>All patients with non-ST elevation acute coronary syndrome should undergo early risk stratification as soon as possible after the diagnosis is secured. The results of risk stratification are used to help choose between immediate coronary angiography, an early invasive strategy, or a conservative approach. (See <a class="local">'Early risk stratification tools'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For early risk stratification, we prefer either the GRACE risk model or the TIMI risk score. (See <a class="local">'TIMI risk score'</a> above and <a class="local">'GRACE risk model'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prior to discharge, patients who have been medically treated and those who have received incomplete revascularization should undergo noninvasive assessment for residual inducible ischemia. (See <a class="local">'Stress testing'</a> above.)</p><p></p><p class="bulletIndent1">In the absence of a specific indication (eg,<strong> </strong>heart failure or suspected mechanical complication), the left ventricular ejection fraction is usually measured before discharge and echocardiography is often the preferred method. If revascularization has been performed, some experts are comfortable waiting until after discharge to obtain an assessment of left ventricular function. (See <a class="local">'Left ventricular function'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37:267.</a></li><li><a class="nounderline abstract_t">Sanchis J, Bodí V, Núñez J, et al. New risk score for patients with acute chest pain, non-ST-segment deviation, and normal troponin concentrations: a comparison with the TIMI risk score. J Am Coll Cardiol 2005; 46:443.</a></li><li><a class="nounderline abstract_t">Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000; 284:835.</a></li><li><a class="nounderline abstract_t">Morrow DA, Antman EM, Snapinn SM, et al. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS. Eur Heart J 2002; 23:223.</a></li><li><a class="nounderline abstract_t">Soiza RL, Leslie SJ, Williamson P, et al. Risk stratification in acute coronary syndromes--does the TIMI risk score work in unselected cases? QJM 2006; 99:81.</a></li><li><a class="nounderline abstract_t">Sabatine MS, McCabe CH, Morrow DA, et al. Identification of patients at high risk for death and cardiac ischemic events after hospital discharge. Am Heart J 2002; 143:966.</a></li><li><a class="nounderline abstract_t">Mega JL, Morrow DA, Sabatine MS, et al. Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Am Heart J 2005; 149:846.</a></li><li><a class="nounderline abstract_t">Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344:1879.</a></li><li><a class="nounderline abstract_t">Sabatine MS, Morrow DA, McCabe CH, et al. Combination of quantitative ST deviation and troponin elevation provides independent prognostic and therapeutic information in unstable angina and non-ST-elevation myocardial infarction. Am Heart J 2006; 151:25.</a></li><li><a class="nounderline abstract_t">Morrow DA, Antman EM, Giugliano RP, et al. A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet 2001; 358:1571.</a></li><li><a class="nounderline abstract_t">Wiviott SD, Morrow DA, Frederick PD, et al. Application of the Thrombolysis in Myocardial Infarction risk index in non-ST-segment elevation myocardial infarction: evaluation of patients in the National Registry of Myocardial Infarction. J Am Coll Cardiol 2006; 47:1553.</a></li><li><a class="nounderline abstract_t">Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003; 163:2345.</a></li><li><a class="nounderline abstract_t">de Araújo Gonçalves P, Ferreira J, Aguiar C, Seabra-Gomes R. TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. Eur Heart J 2005; 26:865.</a></li><li><a class="nounderline abstract_t">Aragam KG, Tamhane UU, Kline-Rogers E, et al. Does simplicity compromise accuracy in ACS risk prediction? A retrospective analysis of the TIMI and GRACE risk scores. PLoS One 2009; 4:e7947.</a></li><li><a class="nounderline abstract_t">Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 2004; 291:2727.</a></li><li><a class="nounderline abstract_t">Fox KA, Fitzgerald G, Puymirat E, et al. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. BMJ Open 2014; 4:e004425.</a></li><li><a class="nounderline abstract_t">Roe MT, Chen AY, Thomas L, et al. Predicting long-term mortality in older patients after non-ST-segment elevation myocardial infarction: the CRUSADE long-term mortality model and risk score. Am Heart J 2011; 162:875.</a></li><li><a class="nounderline abstract_t">McNamara RL, Kennedy KF, Cohen DJ, et al. Predicting In-Hospital Mortality in Patients With Acute Myocardial Infarction. J Am Coll Cardiol 2016; 68:626.</a></li><li><a class="nounderline abstract_t">Bugiardini R, Manfrini O, De Ferrari GM. Unanswered questions for management of acute coronary syndrome: risk stratification of patients with minimal disease or normal findings on coronary angiography. Arch Intern Med 2006; 166:1391.</a></li><li><a class="nounderline abstract_t">Roe MT, Harrington RA, Prosper DM, et al. Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Circulation 2000; 102:1101.</a></li><li><a class="nounderline abstract_t">Diver DJ, Bier JD, Ferreira PE, et al. Clinical and arteriographic characterization of patients with unstable angina without critical coronary arterial narrowing (from the TIMI-IIIA Trial). Am J Cardiol 1994; 74:531.</a></li><li><a class="nounderline abstract_t">Patel MR, Chen AY, Peterson ED, et al. Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative. Am Heart J 2006; 152:641.</a></li><li><a class="nounderline abstract_t">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 130:2354.</a></li><li><a class="nounderline abstract_t">Liebson PR, Klein LW. The non-Q wave myocardial infarction revisited: 10 years later. Prog Cardiovasc Dis 1997; 39:399.</a></li><li><a class="nounderline abstract_t">Solomon SD, Glynn RJ, Greaves S, et al. Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study. Ann Intern Med 2001; 134:451.</a></li><li><a class="nounderline abstract_t">Nijland F, Kamp O, Karreman AJ, et al. Prognostic implications of restrictive left ventricular filling in acute myocardial infarction: a serial Doppler echocardiographic study. J Am Coll Cardiol 1997; 30:1618.</a></li><li><a class="nounderline abstract_t">Møller JE, Søndergaard E, Poulsen SH, Egstrup K. Pseudonormal and restrictive filling patterns predict left ventricular dilation and cardiac death after a first myocardial infarction: a serial color M-mode Doppler echocardiographic study. J Am Coll Cardiol 2000; 36:1841.</a></li><li><a class="nounderline abstract_t">Zornoff LA, Skali H, Pfeffer MA, et al. Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction. J Am Coll Cardiol 2002; 39:1450.</a></li><li><a class="nounderline abstract_t">Moller JE, Hillis GS, Oh JK, et al. Left atrial volume: a powerful predictor of survival after acute myocardial infarction. Circulation 2003; 107:2207.</a></li><li><a class="nounderline abstract_t">Grigioni F, Enriquez-Sarano M, Zehr KJ, et al. Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation 2001; 103:1759.</a></li><li><a class="nounderline abstract_t">Møller JE, Hillis GS, Oh JK, et al. Wall motion score index and ejection fraction for risk stratification after acute myocardial infarction. Am Heart J 2006; 151:419.</a></li><li><a class="nounderline abstract_t">Goodman SG, Barr A, Sobtchouk A, et al. Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: the Canadian ESSENCE ST segment monitoring substudy. J Am Coll Cardiol 2000; 36:1507.</a></li><li><a class="nounderline abstract_t">Scirica BM, Morrow DA, Budaj A, et al. Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) trial. J Am Coll Cardiol 2009; 53:1411.</a></li></ol></div><div id="topicVersionRevision">Topic 76 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26320110" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16053956" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : New risk score for patients with acute chest pain, non-ST-segment deviation, and normal troponin concentrations: a comparison with the TIMI risk score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10938172" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11792137" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16410286" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Risk stratification in acute coronary syndromes--does the TIMI risk score work in unselected cases?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12075250" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Identification of patients at high risk for death and cardiac ischemic events after hospital discharge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15894966" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11419424" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16368287" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Combination of quantitative ST deviation and troponin elevation provides independent prognostic and therapeutic information in unstable angina and non-ST-elevation myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11716882" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16630990" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Application of the Thrombolysis in Myocardial Infarction risk index in non-ST-segment elevation myocardial infarction: evaluation of patients in the National Registry of Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14581255" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Predictors of hospital mortality in the global registry of acute coronary events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15764619" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19956773" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Does simplicity compromise accuracy in ACS risk prediction? A retrospective analysis of the TIMI and GRACE risk scores.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15187054" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24561498" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22093204" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Predicting long-term mortality in older patients after non-ST-segment elevation myocardial infarction: the CRUSADE long-term mortality model and risk score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27491907" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Predicting In-Hospital Mortality in Patients With Acute Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16832004" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Unanswered questions for management of acute coronary syndrome: risk stratification of patients with minimal disease or normal findings on coronary angiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10973837" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8074033" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Clinical and arteriographic characterization of patients with unstable angina without critical coronary arterial narrowing (from the TIMI-IIIA Trial).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16996828" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25249586" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9122424" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The non-Q wave myocardial infarction revisited: 10 years later.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11255520" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9385885" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Prognostic implications of restrictive left ventricular filling in acute myocardial infarction: a serial Doppler echocardiographic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11092654" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pseudonormal and restrictive filling patterns predict left ventricular dilation and cardiac death after a first myocardial infarction: a serial color M-mode Doppler echocardiographic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11985906" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12695291" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Left atrial volume: a powerful predictor of survival after acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11282907" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16442909" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Wall motion score index and ejection fraction for risk stratification after acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11079650" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: the Canadian ESSENCE ST segment monitoring substudy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19371824" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
